Feeds › Ownership stakes (13D / 13G)
Ownership stakes (13D / 13G)
Investors who own more than 5% of a company, from activists (13D) to passive holders (13G).
About this data
- What it is
- An investor who owns more than 5% of a public company must say so. Investors who may try to influence the company, such as activists, file the longer Schedule 13D; passive holders file the shorter Schedule 13G.
- Who files it
- The investor, within days of crossing 5%, and again whenever the stake changes materially.
- How current
- We collect new filings throughout the day on SEC business days.
- Worth knowing
- 13G filings are far more common than 13D. A 13D usually means the investor intends to push for changes, so it tends to get more attention.
All of this comes from public filings.
Source and freshness · Information, not investment advice (disclaimer).
Filings per day, last 30 days
13D (activist) 13G (passive)
Latest ownership filings
Showing: ticker TVRD
| Filed | ScheduleBoth report a stake of more than 5%. A 13D is filed by investors who may try to influence the company, such as activists; a 13G by passive holders. | Company | Investor | Shares | % of shares | Filing |
|---|---|---|---|---|---|---|
| Feb 17, 2026 | SCHEDULE 13G/A (amended) | TVRD Tvardi Therapeutics, Inc. | Ronald A. DePinho | 426,190 | 4.5% | SCHEDULE 13G/A ↗ |
| Nov 14, 2025 | SCHEDULE 13G/A (amended) | TVRD Tvardi Therapeutics, Inc. | Ronald A. DePinho | 626,190 | 6.7% | SCHEDULE 13G/A ↗ |
| Aug 14, 2025 | SCHEDULE 13G | TVRD Tvardi Therapeutics, Inc. | David Greenspan | 704,118 | 7.5% | SCHEDULE 13G ↗ |
| Aug 14, 2025 | SCHEDULE 13G | TVRD Tvardi Therapeutics, Inc. | Slate Path Capital LP | 704,118 | 7.5% | SCHEDULE 13G ↗ |
| Aug 8, 2025 | SCHEDULE 13G | TVRD Tvardi Therapeutics, Inc. | Sporos Bioventures LLC | 837,636 | 8.9% | SCHEDULE 13G ↗ |
| Aug 5, 2025 | SCHEDULE 13G/A (amended) | TVRD Tvardi Therapeutics, Inc. | Samuel D. Tweardy | 315,658 | 3.4% | SCHEDULE 13G/A ↗ |
| Jun 2, 2025 | SCHEDULE 13G | TVRD Tvardi Therapeutics, Inc. | Ronald A. DePinho | 780,990 | 8.3% | SCHEDULE 13G ↗ |
| May 2, 2025 | SCHEDULE 13G | TVRD Tvardi Therapeutics, Inc. | Samuel D. Tweardy | 946,974 | 10.1% | SCHEDULE 13G ↗ |
| May 2, 2025 | SCHEDULE 13G | TVRD Tvardi Therapeutics, Inc. | David J. Tweardy | 652,398 | 7.0% | SCHEDULE 13G ↗ |
| Apr 22, 2025 | SCHEDULE 13G | TVRD Tvardi Therapeutics, Inc. | Solas Partners II, LLC | 761,287 | 8.1% | SCHEDULE 13G ↗ |
| Apr 22, 2025 | SCHEDULE 13G | TVRD Tvardi Therapeutics, Inc. | Solas BioVentures Fund II, LP | 761,287 | 8.1% | SCHEDULE 13G ↗ |
| Apr 22, 2025 | SCHEDULE 13G | TVRD Tvardi Therapeutics, Inc. | Solas Tvardi Sidecar LLC | 761,287 | 8.1% | SCHEDULE 13G ↗ |
| Apr 16, 2025 | SCHEDULE 13D/A (amended) | TVRD Tvardi Therapeutics, Inc. | CSL Limited | 205,465 | 2.2% | SCHEDULE 13D/A ↗ |
| Apr 16, 2025 | SCHEDULE 13D/A (amended) | TVRD Tvardi Therapeutics, Inc. | Vifor (International) Ltd. | 205,465 | 2.2% | SCHEDULE 13D/A ↗ |
14 items, most recent first (up to 50). Every row links to its original filing. Updated Nov 15, 2026, 9:08 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · Clinical trial updates · FDA approvals and clearances